Fresh, sourced stories worth posting about for physicians — updated every few hours, with the receipts attached. Not generated guesses.
Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
Signals about Ozempic/semaglutide and compounded weight-loss drugs cluster around safety warnings, adverse-event concerns, marketing scrutiny, and lawsuit activity involving blindness, gastroparesis, and FDA warning letters.
Draft a post from this →A set of NIH awards highlights broad clinical research activity, including tumor-targeting proteomics, chordoma senolytics, head and neck cancer signaling, suicide risk interventions, pollen allergen quantification, and pediatric catecholamine kinetics.
Draft a post from this →Depo-Provera signals center on updated warnings and legal claims alleging an increased risk of meningiomas and other brain tumors, creating a combined clinical-safety and mass-tort story.
Draft a post from this →Hospital leaders are being pushed to change workflows before their data systems catch up, with Medicare Advantage prior authorization, utilization management, denials, and risk adjustment driving operational friction.
Draft a post from this →Lawsuits over implanted devices, including Bard PowerPort chemo ports and spinal cord stimulators, reflect ongoing concerns about device failure, clotting, injury, and product liability in procedural care.
Draft a post from this →